Braxia Scientific Corp. announced positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial to evaluate the feasibility, safety, tolerability, and efficacy of multi-dose psilocybin-assisted therapy for Treatment-Resistant-Depression. The preliminary results were presented at the "From Research to Reality Conference" in Toronto, May 27-28, 2022.

Positive Preliminary Results Highlights Bxia ScScientific's ongoing multi-dose psilocybin trial effectively demonstrated the fsibility of BrBraxia's proprietary psilocybin-assisted therapy protocol with high rates of recruitment and retention with adequate tolerability and safety. Clinically meaningful improvements in depression severity observed (as measured by the MADRS1) with complete analysis of antidepressant efficacy and secondary outcomes pending. This trial will be completed by December 2022 at which point the full analysis will be completed and submitted for publication.

Preliminary results indicate strong feasibility with adequate recruitment including 159 individuals who were referred to the study. Retention -- 93% of participants retained to primary endpoint. Safety -- No serious adverse events and zero suicide attempts to date.

Tolerability -- majority of adverse effects resolving within 24 hours of each dose and 87% of participants requesting to receive a second dose. Feasibility of Braxia Institute psychedelic therapy training program demonstrated through recruiting, retaining, and training group of multi-disciplinary independently licensed therapists that continue to serve as therapists as part of Braxia's psilocybin trial. Group of therapists consists of psychiatrists, primary care therapists, psychotherapists and spiritual care.

mymptoms of depression were assessed using the Montgomery-Åsberg depressionating scale (MADRS), a widely used and accepted scale for assessing depression. Braxia Scientific was the first to receive Health Canada approval for a multi-dose psilocybin-assisted therapy clinical trial in July 2021, and dosed its first participant in November 2021. This ongoing clinical trial provides Canadians with immediate access to psilocybin for treatment resistant depression.

Recently, Braxia Scientific also recently announced its among the first to receive approval for psilocybin-assisted therapy treatment approval in Ontario using Health Canada's Special Access Program (SAP). The SAP was amended January 5th, 2022 to include access to psychedelic compounds on a case-by-case basis outside of clinical trials.